Post-Discharge Opioid Consumption in TKA and THA Patients Receiving Suzetrigine-Inclusive Multimodal Analgesia: A Prospective Quality Improvement Study
Abstract
Opioid prescribing after total knee (TKA) and total hip arthroplasty (THA) frequently exceeds consumption, leaving unused medication. Multimodal analgesia aims to reduce opioid reliance while maintaining adequate pain control. Suzetrigine, a selective peripheral NaV1.8 inhibitor approved in 2025, offers a non-opioid option; however, its pivotal efficacy trials involved abdominoplasty and bunionectomy rather than arthroplasty.[1] Describing opioid consumption and patient-reported outcomes within a suzetrigine-inclusive arthroplasty regimen can inform prescribing practices and guide future controlled studies.
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.